63 related articles for article (PubMed ID: 19363257)
1. Pathological synergism between amyloid-beta and apolipoprotein E4--the most prevalent yet understudied genetic risk factor for Alzheimer's disease.
Belinson H; Michaelson DM
J Alzheimers Dis; 2009; 17(3):469-81. PubMed ID: 19363257
[TBL] [Abstract][Full Text] [Related]
2. EFAD transgenic mice as a human
Tai LM; Balu D; Avila-Munoz E; Abdullah L; Thomas R; Collins N; Valencia-Olvera AC; LaDu MJ
J Lipid Res; 2017 Sep; 58(9):1733-1755. PubMed ID: 28389477
[TBL] [Abstract][Full Text] [Related]
3. Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches.
Zhong N; Weisgraber KH
Curr Alzheimer Res; 2009 Oct; 6(5):415-8. PubMed ID: 19874264
[TBL] [Abstract][Full Text] [Related]
4. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release.
Koutsodendris N; Blumenfeld J; Agrawal A; Traglia M; Yip O; Rao A; Kim MJ; Nelson MR; Wang YH; Grone B; Hao Y; Thomas R; Zilberter M; Yoon SY; Arriola P; Huang Y
Cell Rep; 2023 Oct; 42(10):113252. PubMed ID: 37863057
[TBL] [Abstract][Full Text] [Related]
5. Rescue of ApoE4-related lysosomal autophagic failure in Alzheimer's disease by targeted small molecules.
Balasubramaniam M; Narasimhappagari J; Liu L; Ganne A; Ayyadevara S; Atluri R; Ayyadevara H; Caldwell G; Reis RJS; Barger SW; Griffin WST
Commun Biol; 2024 Jan; 7(1):60. PubMed ID: 38191671
[TBL] [Abstract][Full Text] [Related]
6. Peripheral ApoE4 Leads to Cerebrovascular Dysfunction and Aβ Deposition in Alzheimer's Disease.
Sun R; Xie C
Neurosci Bull; 2023 Aug; 39(8):1330-1332. PubMed ID: 37093447
[No Abstract] [Full Text] [Related]
7. Severe COVID-19 in Alzheimer's disease: APOE4's fault again?
Xiong N; Schiller MR; Li J; Chen X; Lin Z
Alzheimers Res Ther; 2021 Jun; 13(1):111. PubMed ID: 34118974
[TBL] [Abstract][Full Text] [Related]
8. Novel natural structure corrector of ApoE4 for checking Alzheimer's disease: benefits from high throughput screening and molecular dynamics simulations.
Goyal M; Grover S; Dhanjal JK; Goyal S; Tyagi C; Chacko S; Grover A
Biomed Res Int; 2013; 2013():620793. PubMed ID: 24324968
[TBL] [Abstract][Full Text] [Related]
9. The following article for this Special Issue was previously published and can be found in its respective issue online: "Detection of early Alzheimer's disease-like molecular alterations in a mouse model expressing human ApoE4".
J Neurochem; 2024 Apr; 168(4):e2. PubMed ID: 38607976
[TBL] [Abstract][Full Text] [Related]
10. APOE4 homozygosity is a new genetic form of Alzheimer's disease.
Xu Q; Liang Z; Huang Y
Nat Med; 2024 May; 30(5):1241-1242. PubMed ID: 38710949
[No Abstract] [Full Text] [Related]
11. mTOR: Alzheimer's disease prevention for APOE4 carriers.
Lin AL; Butterfield DA; Richardson A
Oncotarget; 2016 Jul; 7(29):44873-44874. PubMed ID: 27385004
[No Abstract] [Full Text] [Related]
12. APOE4-mediated Alzheimer disease and "Vascular"-"Meningeal Lymphatic" components: towards a novel therapeutic era?
Chen Z; Schwulst SJ; Mentis AA
Mol Psychiatry; 2021 Oct; 26(10):5472-5474. PubMed ID: 34376823
[TBL] [Abstract][Full Text] [Related]
13. Role of apolipoprotein E4 in protecting children against early childhood diarrhea outcomes and implications for later development.
Oriá RB; Patrick PD; Blackman JA; Lima AA; Guerrant RL
Med Hypotheses; 2007; 68(5):1099-107. PubMed ID: 17098371
[TBL] [Abstract][Full Text] [Related]
14. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.
Michaelson DM
Alzheimers Dement; 2014 Nov; 10(6):861-8. PubMed ID: 25217293
[TBL] [Abstract][Full Text] [Related]
15. Is cerebral microbleed prevalence relevant as a biomarker in amnestic mild cognitive impairment and mild Alzheimer's disease?
Rabelo AG; Teixeira CV; Magalhães TN; Carletti-Cassani AFM; Amato Filho AC; Joaquim HP; Talib LL; Forlenza O; Ribeiro PA; Secolin R; Lopes-Cendes I; Cendes F; Balthazar ML
Neuroradiol J; 2017 Oct; 30(5):477-485. PubMed ID: 28714354
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice.
Dolejší E; Liraz O; Rudajev V; Zimčík P; Doležal V; Michaelson DM
J Neurochem; 2016 Feb; 136(3):503-9. PubMed ID: 26526158
[TBL] [Abstract][Full Text] [Related]
17. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.
Liao F; Hori Y; Hudry E; Bauer AQ; Jiang H; Mahan TE; Lefton KB; Zhang TJ; Dearborn JT; Kim J; Culver JP; Betensky R; Wozniak DF; Hyman BT; Holtzman DM
J Neurosci; 2014 May; 34(21):7281-92. PubMed ID: 24849360
[TBL] [Abstract][Full Text] [Related]
18. Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease.
Tamboli IY; Heo D; Rebeck GW
PLoS One; 2014; 9(3):e93120. PubMed ID: 24675880
[TBL] [Abstract][Full Text] [Related]
19. Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.
Belinson H; Kariv-Inbal Z; Kayed R; Masliah E; Michaelson DM
J Alzheimers Dis; 2010; 22(3):959-70. PubMed ID: 20858958
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking.
Fuentealba RA; Liu Q; Zhang J; Kanekiyo T; Hu X; Lee JM; LaDu MJ; Bu G
PLoS One; 2010 Jul; 5(7):e11884. PubMed ID: 20686698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
